Bloomington, Ind. — Cook Medical and EnteraSense, Ltd. have entered into an agreement where Cook will become the exclusive distributor of EnteraSense’s PillSense product in the United States. Cook will begin assuming sales management and marketing responsibilities for the product in Q4 2024. This distribution agreement is a new way for Cook to collaborate with other companies and do business, empowering Cook to offer the innovative PillSense technology to Cook customers.
PillSense is a novel blood-sensing system. After a patient swallows the PillSense capsule, the capsule can accurately detect upper gastrointestinal bleeding (UGIB). The unique system offers significant value to customers as it allows for fast diagnosis and appropriate triaging of patients with suspected UGIB. The U.S. Food and Drug Administration (FDA) approved PillSense in February 2023.
“GI bleeds can be life-threatening. The sooner physicians can diagnose a bleed, the better chance a patient has of survival,” said Meurisse Leahy, director of product management for Cook’s Endoscopy specialty. “Physicians can combine PillSense with our Hemospray and Instinct Plus products to both diagnose and treat gastrointestinal bleeds faster. Through this distribution partnership, we’re excited to expedite delivery of this unique product to healthcare providers.”
“The innovative PillSense system can transform how UGIB patients are diagnosed and deliver significant benefits to patients, clinicians and hospitals. This strategic partnership between EnteraSense and Cook Medical will accelerate the availability of PillSense right across the US,” said Donal Devery, Chief Executive Officer, EnteraSense Ltd.
Distribution agreements like this are another way Cook is evolving to deliver a continuous stream of innovative products to treat more patients. Cook’s partnership with EnteraSense is the third distribution agreement Cook has entered into in 2024. In March, Cook announced distribution agreements for Bentley’s BeBack Catheter and Getinge’s iCast covered stent system. As Cook continues to change in line with its five-year vision, an integral part of the plan is fostering partnerships to diversify product offerings.
To learn more about PillSense, contact your local Cook Medical sales representative, or visit the Cook booth at the 2024 DDW (Digestive Disease Week) conference in Washington, DC, May 19-12, booth number 2401.
About Cook Medical
Since 1963, Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we invent, manufacture and deliver a unique portfolio of medical devices to the healthcare systems of the world. Serving patients is a privilege, and we demand the highest standards of quality, ethics and service. We have remained family owned so that we have the freedom to focus on what we care about: patients, our employees and our communities.
Find out more at CookMedical.com and for the latest news, follow us on Twitter, Facebook and LinkedIn.
About EnteraSense
EnteraSense Limited is a medical device company founded in 2016 by Donal Devery, Dr. Marvin Ryou and Dr. Chris Thompson of Brigham and Women’s Hospital/Harvard Medical School in the United States. Based in Galway, Ireland, EnteraSense has developed an innovative gastrointestinal diagnostic device that can transform how Upper Gastric Bleeds are diagnosed. The company, whose investors include University of Tokyo Edge Capital Partners and Enterprise Ireland, has started its product rollout and is focused on helping clinicians improve patient outcomes.
News coverage of this announcement
Mass Device—Cook Medical to distribute swallowable GI bleeding sensing device
The Irish Times—Galway-based start-up EnteraSense strikes deal with US medtech group
Limerick Post—Cook Medical lands distribution deal for clever pill
Limerick Leader—Limerick firm Cooks up new partnership with producers of revolutionary capsule
BusinessPlus—Cook Medical To Distribute EnteraSense GI Bleed Detection Capsule In US